



Annual report on the liquidity contract with Gilbert Dupont

Market: Euronext Paris
ISIN code / Mnemo: CH0308403085 / GNRO
Web site: www.geneuro.com

Pursuant to the liquidity contract entrusted by GENEURO SA to Gilbert Dupont, as of December 31, 2016, the following assets appeared on the liquidity account:

- Number of shares: 27,778
- Cash balance of the liquidity account: € 360,165.12

As a reminder, as of June 30, 2016, the following resources were booked to the liquidity account:

- Number of shares: 50,212
- Cash balance of the liquidity account: €253,003.06

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA - a new frontier pioneered by GeNeuro since 2006 and based on research by Institut Mérieux and INSERM.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in France at sites in Archamps, Haute-Savoie and Lyon. It has 30 employees and rights to 16 patent families protecting its technology. For more information, visit: www.geneuro.com

Contacts

GeNeuro

Jesús Martin-Garcia
Chairman and CEO
+41 22 794 50 85
investors@geneuro.com

NewCap (France)

Julien Perez (investors)
+33 1 44 71 98 52
Nicolas Merigeau (media)
+33 1 44 71 94 98
geneuro@newcap.eu

Halsin Partners

Mike Sinclair (media)
+44 20 7318 2955
msinclair@halsin.com

LifeSci Advisors

Chris Maggos (investors)
+1 646 597 6970
+41 79 367 6254
chris@lifesciadvisors.com